• Quotes
  • Shortcuts
The Executive's Internet
Thurs, Apr 15th
icon
GoogleAmazonWikipedia
Technology News icon TECHNOLOGY NEWS | disclaimer | more news
TechCrunch profiles the companies, products and events that are defining and transforming the new web. TechCrunch is written by Michael Arrington.: Philippines ‘buy now, pay later' startup Plentina raises $2.2M seed round


spacerspacer

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Johnson'. (Return)

MarketWatch MarketPulseApr 15, 2021
Merck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patients
Shares of Merck & Co. were up 0.1% in premarket trading on Thursday after the drug company said the oral antiviral COVID-19 treatment it is developing with Ridgeback Therapeutics did not help hospitalized patients in a mid-stage clinical trial. The companies now plan to test molnupiravir in non-hospitalized COVID-19 patients in a Phase 3 trial, with plans to file for emergency authorization in the second half of the year. They are also planning to see if the experimental therapy works for post-exposure prophylaxis. In a separate news release, Merck said it is discontinuing MK-7110 as a treatment for patients hospitalized with COVID-19, saying that the Food and Drug Administration's request for additional clinical information would push the launch into 2022. "Merck is now focusing its efforts on advancing molnupiravir, which, as an oral medicine for outpatient use, represents a promising potential new approach, and on accelerating production of Johnson & Johnson's COVID-19 vaccine," Dr. Roy Baynes, chief medical officer for Merck Research Laboratories, said in the release. Merck's stock has gained 6.6% since the start of the year, while the broader S&P 500 is up 9.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



RELATED ARTICLES
Coronavirus tally: Global cases of COVID-19 top138 million and UI.S. death toll above 564,000 (MarketWatch MarketPulse)
Many Evangelicals say they won't be vaccinated against Covid-19. Some experts say distrust and misinformation have played a role - CNN (Google Business News)

MarketWatchApr 15, 2021
Dispatches from a Pandemic: Johnson & Johnson and AstraZeneca sagas illustrate strength of COVID-19 strategy: ‘It was a wise decision to spread the risk'
‘Factories can be hit by a hurricane, run out of a supply, or be hit by contamination that forces them to shut down.'

CNBC BusinessApr 15, 2021
Daily U.S. Covid cases remain above 70,000 amid Johnson & Johnson vaccine pause
The rate of new U.S. Covid cases remains elevated as the country continues efforts to ramp up its vaccination campaign.
TRENDING TAGS
COVID-19vaccine Johnson pandemic & J&J
CoinbaseDebut Bitcoin Trading Crypto listing
StockBuy Earnings Today Coinbase Market
businessCoinbase Citigroup consumer How IPO
MarketCoinbase Stocks Stock debut Premarket
BuyStocks Stock Billion Earnings Coinbase
StocksBuy Earnings These & Market
billionstock Coinbase Billionaire loss estimates
Chinacrackdown Hong Kong ‘It feels
riskCOVID-19 Study blood Vaccine vaccines

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2021 CEOExpress Company LLC